{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:57:56Z","timestamp":1780451876489,"version":"3.54.1"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2017,5,5]]},"DOI":"10.3233\/cbm-161507","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T12:26:45Z","timestamp":1484656005000},"page":"441-449","source":"Crossref","is-referenced-by-count":23,"title":["The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy"],"prefix":"10.1177","volume":"18","author":[{"given":"Murat","family":"Akyol","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Alacacioglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Kucukzeybek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Gumus","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mete","family":"Kara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Varol","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Taskaynatan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku","family":"Oflazoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Bayoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Oktay","family":"Tarhan","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Dokuz Eylul University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-161507_ref1","first-page":"19","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.3233\/CBM-161507_ref2","first-page":"21","article-title":"Aromatase inhibitors: Rationale for use following antiestrogen therapy","volume":"23","author":"Yue","year":"1999","journal-title":"SeminOncol"},{"key":"10.3233\/CBM-161507_ref3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1016121822916","article-title":"Overview of the pharmacology of the aromatase inactivator exemestane","volume":"74","author":"Bruggemeier","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/CBM-161507_ref4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000065475","article-title":"Long-term mortality of women with a diagnosis of breast cancer","volume":"63","author":"Levi","year":"2002","journal-title":"Oncology"},{"key":"10.3233\/CBM-161507_ref5","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-161507_ref6","first-page":"32","article-title":"Estrogen receptors in breast cancer therapy","volume":"3","author":"Osborne","year":"1996","journal-title":"SciMed"},{"key":"10.3233\/CBM-161507_ref7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/CBM-161507_ref8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.3233\/CBM-161507_ref9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.9-2-126","article-title":"Aromatase inhibitors for breast cancer in postmenopausal women","volume":"9","author":"Campos","year":"2004","journal-title":"Oncologist"},{"key":"10.3233\/CBM-161507_ref10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0079-6603(08)61031-4","article-title":"The heparin sulfate-fibroblast growth factor family: Diversity of structure and function","volume":"59","author":"McKeehan","year":"1998","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"10.3233\/CBM-161507_ref11","doi-asserted-by":"crossref","unstructured":"Ornitz DM and Itoh N. Fibroblast growth factors. Genome Biol 2 (2001), REVIEWS3005.","DOI":"10.1186\/gb-2001-2-3-reviews3005"},{"key":"10.3233\/CBM-161507_ref12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","article-title":"Evolution of the FGF and FGFR gene families","volume":"20","author":"Itoh","year":"2004","journal-title":"Trends Genet"},{"key":"10.3233\/CBM-161507_ref13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.3233\/CBM-161507_ref14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11684-013-0244-8","article-title":"Fibroblast growth factor 21 a novel metabolic regulator from pharmacology to physiology","volume":"7","author":"Li","year":"2013","journal-title":"Front Med"},{"key":"10.3233\/CBM-161507_ref15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF-21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev"},{"key":"10.3233\/CBM-161507_ref16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diabres.2010.03.019","article-title":"Distinct association of serum FGF-21 or adiponectin levels with clinical parameters in patients with type 2 diabetes","volume":"89","author":"Eto","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.3233\/CBM-161507_ref17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.metabol.2010.02.016","article-title":"Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction","volume":"60","author":"Mai","year":"2011","journal-title":"Metabolism"},{"key":"10.3233\/CBM-161507_ref18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/157339909789804396","article-title":"The role of fibroblast growth factor 21 (FGF-21) on energy balance, glucose and lipid metabolism","volume":"5","author":"Cuevas-Ramos","year":"2009","journal-title":"Curr Diabetes Rev"},{"key":"10.3233\/CBM-161507_ref19","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"Klotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3233\/CBM-161507_ref20","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic - cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"10.3233\/CBM-161507_ref21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.3233\/CBM-161507_ref22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF-21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"key":"10.3233\/CBM-161507_ref23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/14779072.2014.904745","article-title":"Fibroblast growth factor 21: A promising therapeutic target in obesity-related disease","volume":"12","author":"Cheung","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.3233\/CBM-161507_ref24","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.3233\/CBM-161507_ref25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/09513590.2010.487587","article-title":"Serum fibroblast growth factor 21 levels in polycystic ovary syndrome","volume":"26","author":"Gorar","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.3233\/CBM-161507_ref26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11684-013-0244-8","article-title":"Fibroblast growth factor 21: A novel metabolic regulator from pharmacology to physiology","volume":"7","author":"Li","year":"2013","journal-title":"Front Med"},{"key":"10.3233\/CBM-161507_ref27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol"},{"key":"10.3233\/CBM-161507_ref28","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF-21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.3233\/CBM-161507_ref29","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-alpha represses beta-Klotho expression and impairs FGF-21 action in adipose cells; involvement of JNK1 in the FGF-21 pathway","volume":"153","author":"Diaz-Delfin","year":"2012","journal-title":"Endocrinology"},{"key":"10.3233\/CBM-161507_ref30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","article-title":"Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity","volume":"71","author":"Mraz","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.3233\/CBM-161507_ref31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diabres.2013.04.010","article-title":"Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up","volume":"101","author":"Lenart-Lipi\u0144ska","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.3233\/CBM-161507_ref32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diabres.2012.01.004","article-title":"Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques","volume":"96","author":"An","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.3233\/CBM-161507_ref33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1475-2840-12-124","article-title":"Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease","volume":"12","author":"Shen","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.3233\/CBM-161507_ref34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2010-1326","article-title":"Liver fat but not other adiposity measures influence circulating FGF-21 levels in healthy young adult wins","volume":"96","author":"Tyynismaa","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3233\/CBM-161507_ref35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.3233\/CBM-161507_ref36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/dc11-0294","article-title":"High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects","volume":"34","author":"Chen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.3233\/CBM-161507_ref37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/dmrr.1177","article-title":"Direct effects of FGF-21 on glucose uptake in human skeletal muscle: Implications for type 2 diabetes and obesity","volume":"27","author":"Mashili","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.3233\/CBM-161507_ref38","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1210\/jc.2012-1221","article-title":"Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis","volume":"97","author":"Reinehr","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.3233\/CBM-161507_ref39","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/ijo.2013.10","article-title":"Serum fibroblast growth factor 21 in human obesity: Regulation by insulin infusion and relationship with glucose and lipid oxidation","volume":"37","author":"Straczkowski","year":"2013","journal-title":"International Journal of Obesity"},{"key":"10.3233\/CBM-161507_ref40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/cen.12552","article-title":"Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females","volume":"82","author":"Lynae","year":"2015","journal-title":"Clinical Endocrinology"},{"key":"10.3233\/CBM-161507_ref41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/00365513.2014.900821","article-title":"Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome","volume":"74","author":"Serap","year":"2014","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"key":"10.3233\/CBM-161507_ref42","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/1055-9965.EPI-08-0570","article-title":"Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: A null association","volume":"17","author":"Hernandez","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3233\/CBM-161507_ref43","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1073\/pnas.0812029106","article-title":"Muc1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment","volume":"106","author":"Pitroda","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3233\/CBM-161507_ref44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.breast.2005.08.033","article-title":"Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women","volume":"15","author":"Esteva","year":"2006","journal-title":"Breast"},{"key":"10.3233\/CBM-161507_ref45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.3233\/CBM-161507_ref46","first-page":"12","article-title":"The effect of the aromatase inhibitor letrozole on lipid parameters in postmenopausal women with breast cancer","volume":"11","author":"Nicolaides","year":"2000","journal-title":"A Preliminary Report. Ann. Oncol"},{"key":"10.3233\/CBM-161507_ref47","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0959-8049(01)00155-1","article-title":"Effect of letrozole on the lipid profile in postmenopausal women with breast cancer","volume":"37","author":"Elisaf","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.3233\/CBM-161507_ref48","first-page":"225","article-title":"Effects of the aromatase inhibitor letrozole on breast cell proliferation and bone\/lipid indices in healthy postmenopausal women: Pilot prevention study","volume":"69","author":"Harper-Wynne","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/CBM-161507_ref49","first-page":"51","article-title":"The effect of anastrozole (ArimidexTM) on serum lipids - data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)","volume":"64","author":"Dewar","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/CBM-161507_ref50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1359-6349(04)90900-7","article-title":"Anastrozole therapy and lipid profile: An update","volume":"2","author":"Wojtacki","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.3233\/CBM-161507_ref51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1359-6349(05)80672-X","article-title":"Biochemical markers of the risk for cardiovascular disease in women with early breast cancer treated with anastrozole","volume":"3","author":"Wojtacki","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.3233\/CBM-161507_ref52","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1538-7445.AM2015-1577","article-title":"Levels of Fibroblast Growth Factor 21 (FGF-21) in serum as diagnostic biomarker in patients with breast cancer","volume":"75","author":"Knott","year":"2015","journal-title":"Cancer Res"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-161507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:36Z","timestamp":1777385316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-161507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":52,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/cbm-161507","relation":{},"ISSN":["1574-0153","1875-8592"],"issn-type":[{"value":"1574-0153","type":"print"},{"value":"1875-8592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,5]]}}}